Skip to main content

Table 1 Literatures relevant to the association of aspirin use and survival of patients with lung cancer

From: The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study

Source Year Country Cell type Stage Study design Study base Sample size
(users/non users)
HR (95%CI)
for OS
Ratnasinghe et al. [15] 2004 USA N/A N/A Prospective cohort NHANES I&II 410 (178/232) 0.81 (0.62-1.07)
Cook et al. [11] 2005 USA N/A N/A Randomized, double-blind, placebo-controlled WHS 140 (58/82) 0.70 (0.50-0.99)
Fontaine et al. [16] 2010 UK NSCLC I-III Prospective cohort Hospital based 1765 (412/1353) 0.84 (N/A)
Brasky et al. [17] 2012 USA N/A N/A Prospective cohort VITamin And Lifestyle 434 (83/351) 0.99 (0.74–1.33)
Wang et al. [18] 2015 USA NSCLC III Retrospective cohort Hospital-based 673 (141/532) 0.97 (0.78–1.20)
McMenamin et al. [19] 2015 UK N/A N/A Retrospective cohort Population-based 13,388 (N/A) 1.00 (0.95–1.05)
Veitonmäki et al. [20] 2016 Finland N/A N/A Retrospective cohort FinRSPC 47 (3/44) 1.03(0.85–1.26)
Maddison et al. [21] 2017 UK SCLC N/A Prospective cohort Hospital-based 313 (71/242) 0.987 (0.754-1.293)
Kang et al. et al. [22] 2020 Korea N/A N/A Retrospective cohort Population-based 5938 1.03 (0.97-1.10)
Our work 2020 Taiwan NSCLC Inoperable Retrospective cohort Population-based (NHIRD) 38,842 0.79 (0.75–0.83)
  1. Abbreviations: USA, United States of America; UK, United Kingdom; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; N/A, not available; 95% CI, 95% confidence interval; NHANES, OS, Overall survival; National Health and Nutrition Examination Survey; HR, hazard ratio; FinRSPC, The Finnish Prostate Cancer Screening Trial; NHIRD, National Health Insurance Research Database